Amgen 2009 Annual Report Download - page 106

expiration or cash settlement, be used again for new grants under the 2009 Plan and the shares subject to
such awards will be added back to the pool of available shares under the 2009 Plan as (i) one (1) share if
such shares were subject to an option or stock appreciation right granted under the 2009 Plan and (ii) as 1.9
shares if such shares were subject to awards other than options or stock appreciation rights granted under the
2009 Plan.
(2) This plan has terminated as to future grants. The number under column (a) with respect to this plan includes
approximately 16.44 million shares issuable upon the exercise of outstanding options with a weighted aver-
age exercise price of approximately $58.31, approximately 4.60 million shares issuable upon the vesting of
outstanding restricted stock units and approximately 1.95 million shares issuable upon the vesting of out-
standing performance units based on a target performance, including approximately 0.87 million
performance units granted in 2008 which continue to be subject to performance goals and approximately
1.08 million performance units granted in 2007 for which the performance period ended on December 31,
2009. The maximum that could be earned would be 200% of the units granted in 2008 and 225% of the units
granted in 2007.
(3) The purchases occurred on June 30, 2009 and December 31, 2009 (the “Purchase Dates”) with a purchase of
198,769 shares of Common Stock at a purchase price of $50.29 per shares on June 30, 2009 and 146,984
shares of Common Stock at a purchase price of $53.74 per share on December 31, 2009. Such purchases re-
flect 95% of the closing price of the Common Stock on the applicable Purchase Date.
(4) These plans have terminated as to future grants. These Plans were originally assumed pursuant to the terms
of the merger agreement between Amgen and Immunex which was approved by our stockholders in May
2002. Both plans were previously approved by Immunex’s shareholders. The number under column (a) with
respect to the Amended and Restated 1999 Equity Incentive Plan includes approximately 12.327 million
shares issuable upon the exercise of outstanding options with a weighted average exercise price of approx-
imately $61.41 and approximately 45,000 shares issuable upon the vesting of outstanding restricted stock
units.
(5) This plan has terminated as to future grants. This plan was originally assumed by Amgen in connection with
the merger of Tularik with and into Amgen SF, LLC, a wholly owned subsidiary of Amgen, on August 13,
2004. This plan was previously approved by Tularik’s shareholders.
(6) This plan terminated as to future grants. The number under column (a) with respect to this plan includes ap-
proximately 11.86 million shares issuable upon the exercise of outstanding options with a weighted average
exercise price of approximately $64.35 and approximately 282,000 shares issuable upon the vesting of out-
standing restricted stock units.
(7) These plans have terminated as to future grants. These plans were originally assumed by Amgen in con-
nection with the merger of Abgenix with and into Amgen Fremont Inc., a wholly owned subsidiary of
Amgen, on April 1, 2006. The Amended and Restated 1996 Incentive Stock Plan (1996 Plan) was pre-
viously approved by Abgenix’s shareholders. The number under column (a) with respect to the 1996 Plan
includes approximately 318,000 shares issuable upon the exercise of outstanding options with a weighted
average exercise price of approximately $68.82 and approximately 2,000 shares issuable upon the vesting of
outstanding restricted stock units. The number under column (a) with respect to the Amended and Restated
1999 Incentive Stock Plan includes approximately 1.625 million shares issuable upon the exercise of out-
standing options with a weighted average exercise price of approximately $64.33 and approximately
426,000 shares issuable upon the vesting of outstanding restricted stock units.
(8) This plan has terminated as to future grants. This plan was originally assumed by Amgen in connection with
the merger of Avidia, Inc. with and into Amgen Mountain View Inc., a wholly owned subsidiary of Amgen,
on October 24, 2006.
94